Advertisement

Topics

Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3

02:00 EDT 14 Mar 2018 | InvestorIdeas

March 14, 2018 (Investorideas.com Newswire) H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset.

Original Article: Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3

NEXT ARTICLE

More From BioPortfolio on "Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...